Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A
Published version of a preprint
The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Abstract
The PI3K/AKT/mTOR pathway is often activated in lymphoma through alterations in PI3K, PTEN, and B-cell receptor signaling, leading to dysregulation of eIF4A (through its regulators, eIF4B, eIF4G, and PDCD4) and the eIF4F complex. Activation of eIF4F has a direct role in tumorigenesis due to increased synthesis of oncogenes that are dependent on enhanced eIF4A RNA helicase activity for translation. eFT226, which inhibits translation of specific mRNAs by promoting eIF4A1 binding to 5′-untranslated regions (UTR) containing polypurine and/or G-quadruplex recognition motifs, shows potent antiproliferative activity and significant in vivo efficacy against a panel of diffuse large B-cell lymphoma (DLBCL), and Burkitt lymphoma models with ≤1 mg/kg/week intravenous administration. Evaluation of predictive markers of sensitivity or resistance has shown that activation of eIF4A, mediated by mTOR signaling, correlated with eFT226 sensitivity in in vivo xenograft models. Mutation of PTEN is associated with reduced apoptosis in vitro and diminished efficacy in vivo in response to eFT226. In models evaluated with PTEN loss, AKT was stimulated without a corresponding increase in mTOR activation. AKT activation leads to the degradation of PDCD4, which can alter eIF4F complex formation. The association of eFT226 activity with PTEN/PI3K/mTOR pathway regulation of mRNA translation provides a means to identify patient subsets during clinical development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, the eIF4A inhibitor eFT226 (zotatifin) has entered phase I/II clinical trials for estrogen receptor–positive metastatic breast cancer in combination with fulvestrant and abemaciclib (43, 44).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [44]
Citations
Cites
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Cui, P., Zhang, S., Ding, F., Ali, S., & Xiong, L. (2014) · Genome Biology · doi:10.1186/gb-2014-15-1-r1 · Cited by 2,294
Maurer, U., Charvet, C., Wagman, A. S., Dejardin, E., & Green, D. R. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.02.009 · Cited by 881
Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860
Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799 · cited 1×
“eIF4A or the loss of PDCD4 expression has been associated with poor prognosis in multiple disease indications (2, 12).”
BackgroundS6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell Growth
Dorrello, N. V., Peschiaroli, A., Guardavaccaro, D., Colburn, N. H., Sherman, N. E., & Pagano, M. (2006) · Science · doi:10.1126/science.1130276 · Cited by 731
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635
Analysis of combined drug effects: a new look at a very old problem
Chou, T.-C., & Talalay, P. (1983) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(83)90490-x · Cited by 619
Brownstein, C. A., Beggs, A. H., Homer, N., Merriman, B., Yu, T. W., Flannery, K. C., DeChene, E. T., Towne, M. C., Savage, S. K., Price, E. N., et al. (2014) · Genome Biology · doi:10.1186/gb-2014-15-3-r53 · Cited by 432
Cited by
Nie, S., Zhang, L., Liu, J., Wan, Y., Jiang, Y., Yang, J., Sun, R., Ma, X., Sun, G., Meng, H., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02088-1 · Cited by 170
Protein synthesis control in cancer: selectivity and therapeutic targeting
Kovalski, J. R., Kuzuoğlu‐Öztürk, D., & Ruggero, D. (2022) · The EMBO Journal · doi:10.15252/embj.2021109823 · Cited by 130
Zhou, Z., Tu, Z., Zhang, J., Tan, C., Shen, X., Wan, B., Li, Y., Wang, A., Zhao, L., Hu, J., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02714-1 · Cited by 77
The crosstalk between metabolism and translation
Biffo, S., Ruggero, D., & Santoro, M. M. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.07.022 · Cited by 72
Expression and Functional Roles of Eukaryotic Initiation Factor 4A Family Proteins in Human Cancers
Xue, C., Gu, X., Li, G., Bao, Z., & Li, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.711965 · Cited by 60
Metadata
- Authors
- Thompson, P. A., Eam, B., Young, N. P., Fish, S., Chen, J., Barrera, M., Howard, H., Sung, E., Parra, A., Staunton, J., Chiang, G. G., Gerson-Gurwitz, A., Wegerski, C. J., Nevarez, A., Clarine, J., Sperry, S., Xiang, A., Nilewski, C., Packard, G. K., Michels, T., Tran, C., Sprengeler, P. A., Ernst, J. T., Reich, S. H., & Webster, K. R.
- Affiliations
- eFFECTOR Therapeutics (United States) (US)
- eFFECTOR Therapeutics, Inc., San Diego, California.
- Corresponding author
- Thompson, Peggy A.
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2021-01-01
- Volume
- 20
- Issue
- 1
- Pages
- 26-36
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W3092340104
- Cited by
- 50
- References
- 38
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 6 · 2023: 10 · 2022: 14 · 2021: 11
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- eFFECTOR Therapeutics
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- mRNA translation, B-cell lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, PI3K/AKT/mTOR pathway, PTEN loss, PDCD4, eIF4F, 5' untranslated region, G-quadruplex, predictive biomarkers, drug sensitivity and resistance, antiproliferative activity
- MeSH terms
- Animals, Female, Humans, Oncogenes, RNA, Messenger, Protein Biosynthesis, Biomarkers, Tumor, Lymphoma, B-Cell, Mice, SCID, Mice, Inbred NOD, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Eukaryotic Initiation Factor-4A, Cell Line, Tumor, PTEN Phosphohydrolase, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A. https://app.cochat.ai/papers/10.1158/1535-7163.mct-19-0973
- The paper
- Thompson, P. A., Eam, B., Young, N. P., Fish, S., Chen, J., Barrera, M., Howard, H., Sung, E., Parra, A., Staunton, J., Chiang, G. G., Gerson-Gurwitz, A., Wegerski, C. J., Nevarez, A., Clarine, J., Sperry, S., Xiang, A., Nilewski, C., Packard, G. K., . . . Webster, K. R. (2021). Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-19-0973
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.